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Infants and young children with severe acute malnutrition (SAM) are treated with empiric broad-spectrum antimicrobials.
Parenteral ceftriaxone is currently a second-line agent for invasive infection. Oral metronidazole principally targets small
intestinal bacterial overgrowth. Children with SAM may have altered drug absorption, distribution, metabolism, and elimina-
tion. Population pharmacokinetics of ceftriaxone and metronidazole were studied, with the aim of recommending optimal
dosing. Eighty-one patients with SAM (aged 2–45 months) provided 234 postdose pharmacokinetic samples for total ceftri-
axone, metronidazole, and hydroxymetronidazole. Ceftriaxone protein binding was also measured in 190 of these samples.
A three-compartment model adequately described free ceftriaxone, with a Michaelis–Menten model for concentration and
albumin-dependent protein binding. A one-compartment model was used for both metronidazole and hydroxymetronida-
zole, with only 1% of hydroxymetronidazole predicted to be formed during first-pass. Simulations showed 80 mg/kg once
daily of ceftriaxone and 12.5 mg/kg twice daily of metronidazole were sufficient to reach therapeutic targets.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 There are no published pharmacokinetic data on ceftriaxone
in infants and young children with severe acute malnutrition
(SAM). A small study on oral metronidazole has been con-
ducted, but no information on its major active metabolite is
available. Changes in body composition and metabolism may
affect the distribution and elimination of these agents. Inappro-
priate dosing may result in reduced efﬁcacy, antimicrobial resis-
tance, or increased adverse effects.
WHAT QUESTION DID THIS STUDY ADDRESS?
 What dose of ceftriaxone and metronidazole should be used
in children with SAM who are sick and hospitalized?
WHAT DOES THIS STUDY ADD TO OUR
KNOWLEDGE?
 A dose of 80mg/kg of ceftriaxone (rather than 50mg/kg) is
predicted to maximize target attainment. Twice daily
metronidazole at 12.5mg/kg (rather than 7.5mg/kg three times
daily) may provide a good compromise between achieving circu-
lating target concentrations, maintaining adequate small intesti-
nal concentrations, and reducing caregiver time. Reduced serum
albumin increased the unbound fraction of ceftriaxone. Edema
signiﬁcantly affected the disposition of both drugs, with weight-
based dosing leading to higher exposures, although this does not
appear to warrant dose reduction.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Our data inform optimal dosing in this vulnerable group of
children. Careful prospective study design enables pharmacoki-
netic parameter estimation of two drugs using only three post-
dose samples.
In Sub-Saharan Africa, infants and young children with complicated
severe acute malnutrition (SAM) requiring hospital admission have
a 12 to> 30% inpatient case fatality,1 with bacterial infection being
a common cause. As a result, the World Health Organization
(WHO) recommends that all children admitted to hospital with
SAM receive broad-spectrum antimicrobial treatment, usually with a
combination of a beta-lactam plus aminoglycoside antibiotics.2
Recent studies suggest increasing antimicrobial resistance but there is
no evidence for the efﬁcacy of alternative ﬁrst-line antimicrobial
combinations in this context.3
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Ceftriaxone, a broad-spectrum third-generation cephalosporin,
is a potentially useful ﬁrst-line treatment for children with SAM.
It is inexpensive and, due to its long half-life, only requires once-
daily administration, which is important to overstretched health-
care settings where children with SAM are usually managed.
When assessing its likely antimicrobial efﬁcacy, the free concen-
tration needs to be considered, since ceftriaxone protein binding
is nonlinear, with higher total concentrations being associated
with larger fraction unbound. Its nonlinear concentration effect
is further compounded by increased free fraction with decreasing
plasma proteins, most notably albumin. Models describing non-
linear ceftriaxone protein binding have been developed in special
populations such those as in intensive care.4 SAM is associated
with potentially reduced available plasma proteins, and often
commonly presents with edema, both of which may affect ceftri-
axone disposition.
In addition to sepsis, small intestinal bacterial overgrowth and
intestinal parasitosis are implicated in malabsorption, diarrhea,
and reduced nutritional recovery in children with SAM. Empiric
oral metronidazole, a nitroimidazole antibacterial active against a
wide range of bacteria including anaerobes, is advocated by some
experts,5 and may aid long-term growth recovery,6 but its efﬁcacy
for mortality and nutritional recovery are yet to be studied in an
appropriately designed clinical trial. The pharmacokinetics (PK)
of metronidazole in SAM may be altered with its half-life prior
to nutritional rehabilitation being reported in one study as up to
23 hours.7 Furthermore, its major hydroxy metabolite has around
65% activity compared with the parent drug.8 Hydroxymetroni-
dazole pharmacokinetics have yet to be studied in children with
SAM.
Here we report a study on ceftriaxone and metronidazole
pharmacokinetics in order to deﬁne appropriate dosing for the
sick, hospitalized infants and young children with SAM. This
study forms the initial stage of the First Line Antimicrobials
in Complicated Severe Acute Malnutrition (FLACSAM)
trial (clinicaltrials.gov NCT03174236), which will compare
ceftriaxone (6metronidazole) with standard-of-care antimicrobials
(6metronidazole) in a 23 2 factorial design for outcomes
including mortality and nutritional recovery. An important risk
associated with unrestricted ceftriaxone use is selection for
extended spectrum beta lactamase (ESBL) and resistance to
other antibiotics classes. It will therefore be particularly impor-
tant for the study of real-world resistance development to be
done in the context of optimally efﬁcacious ceftriaxone dosing.
RESULTS
Patients and demographics
A total of 81 infants and young children with SAM were
recruited in three centers in Kenya. A baseline sample was taken
from all patients, and then 234 postdose samples were collected
from which total ceftriaxone, metronidazole, and hydroxymetro-
nidazole was measured. Unbound ceftriaxone was also measured
in 190 of these samples. In 12 patients the baseline sample con-
tained metronidazole and/or hydroxymetronidazole, and in one
patient ceftriaxone was detected in the baseline sample. These
patients were excluded from the pharmacokinetic analysis of the
drug detected in their baseline sample, but retained for analysis of
the other drug. Vomiting following one of the metronidazole
doses occurred in seven patients, whereas two vomited following
two of the doses. The total number of metronidazole doses dur-
ing PK sampling was 572 giving a vomiting rate per dose of 1.6%.
Demographics and clinical presentation are given in Table 1.
Pharmacokinetic structural models
A three-compartment model provided a slightly better ﬁt than a
two-compartment model ( |OFV 27.4) to total ceftriaxone,
with unbound measurements predicted assuming instantaneous
binding with a Michaelis–Menten model (see Methods). For the
simultaneous modeling of metronidazole and hydroxymetronida-
zole, a one-compartment disposition model was adequate for
both, and adding a zero order lag to the ﬁrst order absorption
gave a signiﬁcant improvement in ﬁt (P< 0.05). Allometric scal-
ing9 was added a priori along with a ﬁxed sigmoidal maturation
function on clearance based on glomerular ﬁltration maturation
for ceftriaxone10 and CYP2A6 maturation11 for metronidazole.
Neither maturation model improved ﬁt ( |OFV< 3.84), but
nor was the ﬁt worsened, and so they were retained in the model
as biological priors for extrapolation. In the case of metronida-
zole, initial model building excluded patients who vomited
within 2 hours of a dose, but including these patients did not
noticeably change the goodness-of-ﬁt, and the largest change in
parameter estimate was a 15% decrease in clearance. Since one
would expect lost dosing due to vomiting if anything to increase
apparent clearance, it was decided to retain these samples.
Hydroxymetronidazole was described using a semimechanistic
model allowing formation from both ﬁrst-pass and circulating
drug, the model with only formation from circulating drug giving
a signiﬁcantly worse ﬁt (P< 0.001). A low extraction ratio of
around 1% indicated most hydroxymetronidazole is formed from
systemic metronidazole. Both models terminated with successful
covariance steps, and model parameters are reported in Table 2.
NONMEM code and model diagnostics for both models are pro-
vided in the Supplementary Materials.
Edema significantly affects disposition
For both ceftriaxone and metronidazole, adding edema as a
covariate on body weight in the allometric model for volume
improved ﬁt. In the case of ceftriaxone, the largest drop in objec-
tive function (OFV) was associated with decreased apparent
weight on volume parameters in the allometric model with any
grade of edema of 26%. For metronidazole the effect of edema
was less pronounced, with the largest OFV drop occurring with
an edema score of 2 or more leading to a decrease in apparent
weight of 17%.
Ceftriaxone clearance associated with renal function and
protein binding predicted from serum albumin
Free ceftriaxone clearance was signiﬁcantly (P< 0.001) associ-
ated with age-corrected serum creatinine.12 Free ceftriaxone
was modeled directly, with total ceftriaxone predicted by
assuming instantaneous binding and a concentration-dependent
Michaelis–Menten model. Albumin was found to signiﬁcantly
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(P< 0.001) improve the ﬁt when added to the Bmax parameter
in the Michaelis–Menten model, with lower serum albumin
being associated with higher fraction unbound. Figures 1 and 2
show visual predictive checks for the ceftriaxone and metronida-
zole ﬁnal models, respectively. Basic goodness-of-ﬁt plots, a plot
of fraction unbound vs. total concentration with different albu-
min concentrations, and a schematic of the ﬁnal model is pro-
vided in the Supplementary Materials.
Probability of target attainment to inform dosing
Fraction time above MIC (ft>MIC) for ceftriaxone free concen-
tration over the ﬁrst 24 hours was simulated for 50, 80, and
100mg/kg once daily dosing (Figure 3). For metronidazole the
sum of the free concentration and 0.65 multiplied by the free
hydroxymetronidazole concentration was used to simulate twice-
daily dosing regimens of 10, 12.5, and 15mg/kg with ft>MIC
and AUC:MIC ratio calculated for the 24 hour periods 0–24
hours and 24–48 hours (Figure 4). The effects of included cova-
riates on pharmacodynamic target attainment are presented in
Figure 5.
DISCUSSION
This is, to our knowledge, the ﬁrst detailed pharmacokinetic
study of ceftriaxone in infants and young children with SAM,3
and we have also augmented the limited available data on oral
metronidazole pharmacokinetics in this population.7 Edema, a
common feature of SAM, signiﬁcantly affected the disposition of
ceftriaxone, and to a lesser extent metronidazole, with patients
having a lower volume of distribution than would be expected
from their total body weight. This did not translate into marked
changes in circulating concentrations or produce a clear indica-
tion of the need for dose reduction (Figure 5), indicating clear-
ance is more important for ft>MIC than volume of distribution
in this case. While no other covariates were signiﬁcant for metro-
nidazole, in common with previous studies we found decreased
ceftriaxone clearance with worsening renal function13 and also, as
expected, the fraction unbound signiﬁcantly related to serum
albumin.4 Again, as expected,14 changes in albumin had no effect
on free drug concentration or target attainment. As in previous
studies,15–17 rather than use a model-based estimate of creatinine
clearance we used serum creatinine scaled by the age appropriate
typical value12 to identify patients deviating from an expected
normal value. This is a similar principle to using a creatinine
clearance value scaled to 1.73m2 but that approach only delin-
eates size-related changes in expected creatinine clearance, not
age. In terms of the impact of covariates on target attainment,
simulations showed that albumin was not an important predictor
of free ceftriaxone, whereas patients with low serum creatinine
had reduced ceftriaxone target attainment (Figure 5). The degree
of this reduction, however, was not sufﬁcient to necessitate dose
increases in these patients.
In this study precise pharmacokinetic parameter estimates were
obtained with low shrinkage (see Table 2) 18 using only three
postdose samples. This is due to a careful sampling schedule,
which although not deﬁned with optimal design methods,
followed the general principle of sampling close to the likely
Table 1 Demographics of all patients, and those included in the ceftriaxone and metronidazole pharmacokinetic analyses
Variable All patients (n581)
Included in ceftriaxone
analysis (n580)
Included in metronidazole
analysis (n569)
Age (mo) 14 (2–45) 15 (2–45) 17 (2–45)
Weight (kg) 5.88 (2.53–10.9) 5.88 (2.53–10.9) 5.88 (2.53–10.9)
Sex (m/f) 35/46 35/45 30/39
Height (cm) 69.4 (50.8–89) 69.7 (50.8–89) 69.4 (50.8–89)
Na1 (mmol/L) 137 (109–165) 137 (109–165) 137 (109–165)
K1 (mmol/L) 3.8 (0.7–7) 3.8 (0.7–7) 3.9 (0.7–7)
Hemoglobin (g/dL) 9 (4.4–12.8) 9 (4.4–12.8) 9 (4.4–12.8)
WBC (x109/L) 14.1 (4.8–58.1) 14.35 (4.8–58.1) 13.5 (4.8–58.1)
Neutrophils (x109/L) 5.27 (1.2–66.4) 5.4 (1.2–66.4) 5.27 (1.2–66.4)
Lymphocytes (x109/L) 5.39 (1.5–17.82) 5.36 (1.5–17.82) 5.3 (1.5–17.82)
Platelets (x109/L) 397 (19–775) 398 (19–775) 375 (19–775)
Albumin (g/L) 33.6 (7–57) 33.75 (7–57) 30.7 (7–57)
Total protein (g/L) 59 (11–92) 59 (11–92) 58 (11–90)
Creatinine (micromol/L) 21 (4–178) 21 (4–178) 20 (4–178)
AST (IU/L) 53 (6–758) 53 (6–758) 52 (6–270)
Edema grade (0/1/2/3) 45/13/14/9 45/12/14/9 37/11/13/8
Median weight by edema grade (kg) 5.18/5.88/8/8.13 5.18/5.88/8/8.13 5.18/5.88/8.14/7.96
Median and range are presented for continuous variables.
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Cmax to give information on distribution, late samples aiming to
cover at least three expected half-lives to inform on clearance,
and samples in the expected absorption phase for oral metronida-
zole. By randomizing patients to different combinations of early,
middle, and late sampling points, in a similar manner to a previ-
ous antimicrobial study in this population,19 study invasiveness
was minimized while maximizing information content. This
approach exempliﬁes the beneﬁts of careful study design, avoiding
the problems that can be caused with opportunistic and scav-
enged sampling.20
Unlike some ceftriaxone pharmacokinetic studies,21 we mea-
sured both total and free ceftriaxone from patient samples, and
under the assumption that only free ceftriaxone was available for
distribution, elimination, and antimicrobial activity, it was mod-
eled directly rather than being inferred from total concentra-
tions.4 Due to the expense of measuring free ceftriaxone, it was
not performed in every sample and where possible we aimed to
obtain free concentrations from an early and a late sample in
order to maximize data on the concentration range from that
individual. Previous studies have not directly modeled free
Table 2 Parameter estimates scaled to a 70 kg individual from the ceftriaxone and metronidazole models. Pharmacokinetic parame-
ters for ceftriaxone relate to free concentrations, except V1 which is the total ceftriaxone central volume. CLIMET is the metronida-
zole intrinsic clearance to hydroxymetronidazole, CLMET is the apparent clearance of metronidazole by other routes, and CLOH the
clearance of hydroxymetronidazole.
Parameter Estimate (bootstrap 95% CI) IIV (bootstrap 95% CI) Shrinkage (%)
Ceftriaxone
CL (L/h) 4.62 (4.06,5.24) 42 (33,49) 3.3
V1 (L) 14.46 (9.47,17.76) 43 (28,71) 17.9
0.93 (0.16,5.61) — —
Q2 (L/h) 6.05 (2.01,18.67) — —
V2 (L) 29.98 (20.32,68.15) — —
Q3 (L/h) 19.26 (12.39,25.98) — —
V3 (L) 69.77 (54.65,87.64) 42 (26,55) 17.1
BM (mg/h) 22.89 (17.43,30.57) — —
KD (mg/L) 0.56 (0.21,0.92) — —
uALB –0.26 (–0.41,–0.12) — —
uSECR –0.26 (–0.36,–0.14) — —
uODEM_CEF 27 (19,33) — 21.4
rPROP_FREE (%) 19 (15,22) — 21.0
rPROP_TOT (%) 4.62 (4.06,5.24) 42 (33,49) 3.3
rADD_TOT (mg/L) 14.46 (9.47,17.76) 43 (28,71) 17.9
Metronidazole
Ka (/h) 0.39 (0.29,0.6) 79 (63,97) 13.9
CLIMET (L/h) 0.74 (0.51,1.08) 61 (47,76) 5.2
CLMET (L/h) 0.51 (0.23,0.76) — —
VMET (L) 56.35 (47.73,65.48) 38 (27,45) 18.3
CLOH (L/h) 1.45 (1.08,1.95) — —
VOH (L) 16.89 (11.67,24.77) — —
Alag (h) 0.17 (0.11,0.26) — —
uODEM_MET –0.17 (–0.31,–0.01) — —
rPROP_MET (%) 32 (27,37) — 17.7
rPROP_OHMET (%) 29 (24,33) — 17.7
rPROP_OHADD (mmol/L) 0.01 (0.002,0.04) — 17.7
Covariates entered the model as follows: BM5 TVBM(Alb/33.75)
uALB where Alb the individual albumin and 33.75 the median; CL5 TVCL(SCR/MSCR)uSECR where SCR is
the individual serum creatinine, and MSCR the expected serum creatinine for age; WTC5WT(11uODEM_CEF or uODEM_MET) where WTC is the corrected weight for patients
with edema used in the allometric scaling model. NONMEM code is provided in the Supplementary Material.
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ceftriaxone; rather, the tendency has been to model total ceftriax-
one and infer free concentrations from this. If only free ceftriax-
one is available for distribution and elimination, modeling total
ceftriaxone would appear to be problematic, since its nonlinear
protein binding means volume of distribution will change with
total concentration. We used a method similar to that of a recent
study on cefazolin,24 whereby total concentration in the central
compartment was used to predict free concentration and free
fraction, and it was only the free fraction that was available for
elimination and distribution. Full details of the model, including
NONMEM code, are provided in the Supplementary Material.
Comparing our model parameters with other studies is compli-
cated by many reporting parameters for total ceftriaxone and a
lack of standardization of age and weight (or size) scaling.9 Our
free ceftriaxone clearance estimate standardized to a 70 kg mature
individual with normal creatinine for age and gender was 4.62 L/
h. This estimate is slightly lower than patients without renal
impairment in a recent report of adult intensive care patients
(6.2 L/h), higher than the neonatal-reported value of 1.61 L/h/
1.73m2,25 but lower than the 14.86 L/h reported in healthy adult
volunteers.26 Regarding protein binding, our dissociation con-
stant (Kd) of 22.9mg/L is similar to the value (28.7mg/L) that
was recently reported by Schleibinger et al.4 No effect of adding
maturation functions to clearance parameters in either the ceftri-
axone or metronidazole models was found, most likely because
most of our patients would be predicted close to the mature value
by their age and we only had data in the upper part of the matu-
ration curve. For example, our youngest patient had a postmenst-
rual age of 46 weeks, which is approximately the half-mature
value in the renal clearance model.10 The rationale for retaining
maturation functions is to provide biological prior information
in case the models were to be used for extrapolation to younger
patients.
When using the model for simulation of pharmacodynamic
target attainment, we chose not to follow the traditional method
of deﬁning a single target and simulating the probability of target
attainment (PTA) against ascending MIC values. Our reasons for
this are twofold: ﬁrst, such plots tend to give measures of spread
of target attainment across the population; second, the preferred
target may not be ﬁxed, with recent work showing that different
populations may require different ft>MIC values.27 We there-
fore chose to plot the actual target (ft>MIC or AUC:MIC)
with ascending MIC values, along with important percentiles
from the simulations. This therefore shows not just the simulated
typical patient, but, for example, the 5th percentile shows the
minimum target attainment expected in 95% of patients. We
would suggest that presenting antimicrobial simulation data in
this way (Figures 3 and 4) provides more information than the
traditional PTA curve.
By parameterizing the model in terms of free ceftriaxone, simu-
lations of free concentrations were therefore straightforward, and
the ft>MIC, which is the index usually found to correlate with
antimicrobial activity,28 was simulated for a range of MIC values
(Figure 3). A common target for beta lactam antimicrobials is to
achieve a ft>MIC of at least 50% of the dosing interval, and typ-
ically Enterobacteriaciae with MICs below 1mg/L, were consid-
ered susceptible, although 2mg/L is now a more common
breakpoint, with MIC >8mg/L indicating the need to test for
the presence of ESBL.29 Our simulations show that for 50mg/kg
dosing there is a greater than 95% probability of having 50% of
the dose interval with concentrations exceeding 2mg/L and
increasing the dose to 80mg/kg improves this to 95% of patients
of patients having greater than 60% of the dose interval exceeding
2mg/L, and greater than 80% of patients achieving 50% above
8mg/L (the ESBL breakpoint).
Including metronidazole formation from ﬁrst-pass and circu-
lating concentrations gave a 70.8 point lower objective function
value than when only circulating concentrations were allowed to
form metabolite, and hence it was retained despite the small frac-
tion (around 1%) formed in this way. In the standard parent
metabolite model, allowing formation from circulation and ﬁrst-
pass is not uniquely identiﬁable since the formation rate cannot
be separated from the fraction metabolized.30 Using the well-
stirred hepatic metabolism model, the formation rate is bounded
by liver plasma ﬂow, and hence the intrinsic clearance parameter
is the only parameter estimated. This is a similar approach to
Figure 1 Prediction corrected visual predictive check (VPC) for total and
unbound ceftriaxone (top row) showing model simulated 95% confidence
intervals for the simulated 2.5th, 50th, and 97.5th percentiles.
Figure 2 Prediction corrected visual predictive check (VPC) for metronida-
zole and hydroxymetronidazole showing model simulated 95% confidence
intervals for the simulated 2.5th, 50th, and 97.5th percentiles.
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that taken in a study of oseltamivir carboxylate formation
from oseltamivir,31 and gave a good description of our data (see
Figure 2). Without intravenous data the model parameters esti-
mated, however, are still apparent, since the total bioavailability is
not identiﬁable. An investigation of parameter identiﬁability and
parameter interpretation is provided in the Supplementary
Materials. Including hydroxymetronidazole was important, since
it is known to have antimicrobial activity in its own right.32 Our
decision to sample patients up to 72 hours post ﬁrst-dose based
on previous data in this population7 was clearly justiﬁed, as accu-
mulation can be seen for both metronidazole and hydroxymetro-
nidazole (Figure 2).
The pharmacodynamic target of metronidazole in this setting
is somewhat unclear. While time above an MIC cutoff of 8mg/
L33 or AUC(0-24)/MIC of 708 have been proposed, and could
potentially be used to justify once-daily dosing along with the use
of a loading dose, when treating small intestinal overgrowth it
could be argued that local upper gastrointestinal tract concentra-
tions maybe more important for efﬁcacy. Taking our estimated
absorption rate constant and assuming a gut lumen volume of
100mL (dose taken with food/drink) a 12.5mg/kg dose adminis-
tered to an 8-kg child would leave a local concentration of
7.3mg/L prior to the next dose. Twice-daily dosing would also
give acceptable AUC and ft>MIC target attainment (Figure 4).
Although twice-daily dosing requires higher volumes of suspen-
sion to be administered, only 1.6% of doses in this study were fol-
lowed by the patient vomiting. It should, however, be noted that
we did not ﬁnd vomiting within 2 hours of a dose to affect met-
ronidazole PK estimates when they were included in the analysis.
A dose of 12.5mg/kg twice daily gives a total daily dose of
25mg/kg, which is slightly higher than the current recommended
dose (7.5mg/kg three times, giving 22.5mg/kg/day).
In conclusion, for children who are severely ill with compli-
cated SAM, this study supports doses of i.v. ceftriaxone 80mg/kg
once daily, which is in line with recent WHO recommendations.
Our suggested dosing of oral metronidazole 12.5mg/kg twice
daily provides a simpliﬁed regime that should maintain efﬁca-
cious upper gastrointestinal tract concentrations.
METHODS
Patient recruitment
A three-center open-label phase II PK study was undertaken in children
aged 2–59 months with severe acute malnutrition (SAM). For children
aged 6–59 months, SAM was deﬁned as kwashiorkor (edematous malnu-
trition) or a middle upper arm circumference (MUAC) less than
11.5 cm, or weight-for-height Z-score of less than –3. For children aged
1–5 months SAM was deﬁned as kwashiorkor or MUAC less than
11 cm or weight-for-height Z score less than –3. Infants with weight less
than 2.5 kg were excluded. The study received favorable ethical review
from the Kenya Medical Research Institute Review Committee, Nairobi,
the Oxford Tropical Research Ethics Committee, Oxford, UK, and the
Kenyan Expert Committee on Clinical Trials of the Pharmacy & Poi-
sons Board, and is registered with clinicaltrials.gov (NCT02746276).
Parents of eligible patients were approached for informed consent.
Drug administration, sampling, and assay
Enrolled patients received ceftriaxone 50mg/kg (or 100mg/kg if menin-
gitis suspected) 24 hourly by intravenous bolus (250mg or 500mg vials,
Roche, Nutley, NJ), and metronidazole 7.5mg/kg 8 hourly by oral sus-
pension (200mg/5mL, Sanoﬁ, Bridgewater, NJ). PK samples were taken
up to 72 hours following the ﬁrst dose. A baseline PK sample was taken
and then the ﬁrst metronidazole dose followed by the ﬁrst ceftriaxone
dose. To minimize study invasiveness, only three further PK samples
were taken. Patients were randomized to one of three possible early, mid-
dle, and late samples as follows: Early: 5 minutes, 30 minutes, or 1 hour
post ﬁrst dose; Middle: 2 hours, 4 hours, or 8 hours post ﬁrst dose; Late:
24 hours, 48 hours, or 72 hours post ﬁrst dose with exact dosing and
sampling time recorded to the nearest minute.
Samples were analyzed for total ceftriaxone, metronidazole, and
hydroxymetronidazole. Free ceftriaxone was also measured in a subset
of samples, with preference given to the early and late timepoints.
Full details on the assay were recently published by Ongas et al.35
Brieﬂy, a reversed-phase high-performance liquid chromatography
Figure 3 ft>MIC for 50, 80, and 100 mg/kg once daily. The 5th, 10th, 20th, and 50th percentiles show the cutoffs for ft>MIC for 95, 90, 80, and 50%
of patients, respectively. Lines at a MIC cutoff of 2 mg/L and ft>MIC of 0.5 show the proposed MIC target.
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Figure 4 Simulations for free metronidazole plus hydroxymetronidazole under 10, 12.5, and 15 mg/kg twice daily dosing, with hydroxymetronidazole
concentrations being multiplied by 0.65 to reflect the assumed lower activity. A break-point of 8 mg/L is highlighted. (a) Yhe ft>MIC with a value of 0.9
highlighted; whereas (b) shows the AUC:MIC ratio with a cutoff of 70 mg.h/L highlighted. A comparison of 24- and 48-hour target attainment is given in
the upper and lower panels, respectively.
1171CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 104 NUMBER 6 | December 2018
        ARTICLE
method coupled with electrospray ionization mass spectrometry
(HPLC–ESI-MS/MS) method was developed requiring 50 lL of
plasma for simultaneous ceftriaxone, metronidazole, and hydroxyme-
tronidazole quantiﬁcation (a further 25 lL was required for ultraﬁl-
tration and free ceftriaxone quantiﬁcation). The intra- and interrun
precision was less than 9% and the lower limits of quantiﬁcation were
0.4, 0.05, and 0.02 lg/mL for ceftriaxone, metronidazole, and hydrox-
ymetronidazole, respectively.
Pharmacokinetic model building
Unbound ceftriaxone was ﬁrst analyzed alone to derive a base structural dis-
position model, with one-, two-, and three-compartment disposition models
tested. It was assumed that bound drug is unavailable for elimination, distri-
bution, or pharmacological effect, so when total concentrations were added,
free concentration (CU) was predicted from total concentration (CT) in the
central compartment, with bound concentration (CB) assumed to follow
Michaelis–Menten kinetics with instantaneous binding:
CB5
BmaxCU
Kd1CU
where Bmax and Kd are the estimated Michaelis–Menten parameters, and
CT5CU1CB . The unbound concentration was therefore derived from
the Michaelis–Menten equation above:
CU5
1
2

ðCT2Bmax2KdÞ1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðCT2Bmax2KdÞ214KdCT
q 
Metronidazole and hydroxymetronidazole were simultaneously ﬁtted using
the well-stirred liver model, using a similar model to previous study on osel-
tamivir carboxylate formation from oseltamivir.31 A common absorption
rate constant and ﬁxed hepatic plasma ﬂow were used to allow for both
ﬁrst-pass and hydroxymetronidazole formation from circulating drug to be
identiﬁed. Structural and practical model identiﬁability is discussed in the
Supplementary Material. Hepatic plasma ﬂow was derived from an allo-
metrically scaled adult hepatic blood ﬂow (73L/h) scaled by measured
hematocrit according to the expression reported by Price et al.36:
QHP576
w
70
 0:75
ð12h0:91Þ
where QHP is hepatic plasma ﬂow, w is body weight in kg, and h is the
hematocrit. The fraction transformed to hydroxymetronidazole during
ﬁrst-pass was assumed to be 1 minus the extraction ratio (ER) and
hepatic clearance of circulating metronidazole to hydroxymetronidazole
was given by the following:
CLM5QHPER5QHP
CLI
CLI1QHP
where the intrinsic clearance, CLI, was an estimated parameter. Clear-
ance of metronidazole by other routes was assumed to be linear, as was
clearance of hydroxymetronidazole.
Biological prior information in the form of allometric scaling with
exponents of 0.75, 1, and –0.25 for all clearance volume and absorption
rate parameters, respectively, was added a priori. Furthermore, a
maturation function for renal clearance based on a previous study10 was
used to scale free ceftriaxone clearance and hydroxymetronidazole clear-
ance. Metronidazole hydroxylation at the 2 position is catalyzed by
CYP2A6,37 and hence the CYP2A6 maturation function reported by
Upreti et al.11 was used to scale CLI.
Further covariates tested in the following order were: albumin and
total plasma protein on Bmax, age corrected serum creatinine on free cef-
triaxone clearance and hydroxymetronidazole clearance, and edema to
scale weight in the allometric models. The likelihood ratio test was used
to determine covariate inclusion, with an improvement in –2 log likeli-
hood of> 3.84 considered signiﬁcant. Model diagnostics included plots
of observations vs. population predictions, conditional weighted residuals
(CWRES) vs. time and prediction, and individual proﬁle plots. Simula-
tion properties were tested with a visual predictive check (VPC). Param-
eter stability was investigated using a nonparametric bootstrap. Modeling
was undertaken using NONMEM v. 7.338 using the ﬁrst-order condi-
tional estimation algorithm with interaction (FOCEI). Perl-speaks
NONMEM (PsN) was used for VPC and bootstrap preparation,39 and
data manipulations and plotting were performed using R v. 3.2.
Pharmacodynamic simulations
A simulated population of 1,000 subjects with demographics sampled
from the study population was generated and the ceftriaxone model was
used to simulate the ft>MIC for MIC values in the range 0.25–8mg/L.
The 5th, 10th, 20th, and 50th percentiles were presented to show the
minimum ft>MIC for 95, 90, 80, and 50% of patients, respectively. A
target of 0.5 for ft>MIC with a MIC cutoff of 2mg/L (the current
EUCAST resistance breakpoint) was considered. For metronidazole, a
pharmacodynamic target of area under the curve to MIC ratio AUC(0-
24)/MIC of 708 and the ft>MIC of 8mg/L were investigated.33 Simu-
lations for once, twice, and three-times daily dosing were performed,
Figure 5 Boxplots to illustrate simulated covariate effects on translation to ft>MIC. Probability of target attainment reported beneath each box with a
target of 50% of the dosing interval with concentrations above 2 mg/L at 24 hours for free ceftriaxone, and 90% of the dosing interval with concentrations
of free metronidazole and 0.65 x hydroxymetronidazole above 8 mg/L at 48 hours. (a) Effect of edema score of 1 or more on ceftriaxone target attain-
ment. (b) Effect of edema score of 2 or more on metronidazole target attainment. (c) Effect of serum creatinine on ceftriaxone target attainment.
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along with consideration of a loading dose. In these simulations 10%
protein binding was assumed for parent and metabolite, and hydroxyme-
tronidazole concentrations multiplied by 0.65 were added to metronida-
zole under the assumption of hydroxymetronidazole having 65% of its
parent’s antimicrobial activity.32 The results of all simulations for ceftri-
axone and metronidazole were presented in a report to the FLACSAM
trial steering committee to agree on dosing for the main trial.
Additional Supporting Information may be found in the online version of
this article.
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